These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26822399)

  • 1. Lessons from breast cancer trials of HER2-kinase inhibitors.
    Krop IE
    Lancet Oncol; 2016 Mar; 17(3):267-268. PubMed ID: 26822399
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting alternative pathways in HER2-positive breast cancer.
    Rastogi P
    Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
    [No Abstract]   [Full Text] [Related]  

  • 3. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 6. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?
    Loibl S
    JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeted therapies in breast cancer].
    Jerusalem G; Collignon J; Rorive A; Lifrange E; André C; Martin M; Maweja S; Coucke P
    Rev Med Liege; 2011; 66(5-6):379-84. PubMed ID: 21826980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of HER2 - twice as good or twice as toxic?
    Fralick M; Hilton JF; Bouganim N; Clemons M; Amir E
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):593-603. PubMed ID: 22748560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib in the treatment of breast cancer.
    Hurvitz SA; Shatsky R; Harbeck N
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1039-47. PubMed ID: 24870559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
    Flaherty KT; Brose MS
    Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New treatment approaches in breast cancer].
    Spirig C; Thürlimann B; Huober J
    Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 17. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 as a cancer stem-cell target.
    Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
    Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
    [No Abstract]   [Full Text] [Related]  

  • 19. Ten years of HER2-directed therapy: still questions after all these years.
    Krop IE; Winer EP
    Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
    [No Abstract]   [Full Text] [Related]  

  • 20. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.